| Literature DB >> 34836991 |
Reza A Badian1, Stephan Allgeier2, Fabio Scarpa3, Mattias Andréasson4,5,6, Andreas Bartschat2, Ralf Mikut2, Alessia Colonna3, Marco Bellisario7, Tor Paaske Utheim8,9, Bernd Köhler2, Per Svenningsson4,5,6, Neil Lagali10,11.
Abstract
In vivo confocal microscopy (IVCM) is a non-invasive imaging technique facilitating real-time acquisition of images from the live cornea and its layers with high resolution (1-2 µm) and high magnification (600 to 800-fold). IVCM is extensively used to examine the cornea at a cellular level, including the subbasal nerve plexus (SBNP). IVCM of the cornea has thus gained intense interest for probing ophthalmic and systemic diseases affecting peripheral nerves. One of the main drawbacks, however, is the small field of view of IVCM, preventing an overview of SBNP architecture and necessitating subjective image sampling of small areas of the SBNP for analysis. Here, we provide a high-quality dataset of the corneal SBNP reconstructed by automated mosaicking, with an average mosaic image size corresponding to 48 individual IVCM fields of view. The mosaic dataset represents a group of 42 individuals with Parkinson's disease (PD) with and without concurrent restless leg syndrome. Additionally, mosaics from a control group (n = 13) without PD are also provided, along with clinical data for all included participants.Entities:
Mesh:
Year: 2021 PMID: 34836991 PMCID: PMC8626466 DOI: 10.1038/s41597-021-01087-3
Source DB: PubMed Journal: Sci Data ISSN: 2052-4463 Impact factor: 6.444
Study parameters related to the IVCM data obtained and provided in the mosaic dataset.
| Parameter | Description |
|---|---|
| Subject ID | Identification number assigned to each of the subjects in the study cohort (1 to 57) |
| Image name | File name assigned to each image in the wide-field mosaics dataset |
| Eye | Image and clinical data corresponding to right eye (RE) or left eye (LE) |
| Mosaic area | Area of the corneal subbasal nerve plexus represented in the mosaic image (mm2). In all cases, regions without image data (black or empty areas) were not included in the area calculation. |
| mCNFL | Mosaic corneal nerve fiber length density: the total length of all nerves in the mosaic divided by the mosaic area expressed in (mm/mm2) |
| mCNBD | Mosaic corneal nerve branch density; defined as total number of branching points divided by the mosaic area and expressed as the number of branching points per mm2 (nr./ mm2) |
| wCNFL | Whorl corneal nerve fiber length density; defined as corneal subbasal nerve fiber length density in the whorl region (in mm/mm2), based on automated nerve tracing. wCNFL is provided for 800 µm and 400 µm diameter whorl regions in full and half-circle areas (see Fig. |
| wCNBD | Whorl corneal nerve branch density defined as total number of branching points in the whorl region divided by the mosaic area expressed as the number of branching points per mm2. wCNBD is provided for the four different definitions of the whorl as for wCNFL. |
| mDCs | Density of mature dendritic cells in each mosaic, in cells/mm2 of mosaic area. |
| imDCs | Density of immature dendritic cells in each mosaic, in cells/mm2 of mosaic area. |
| GCs | Density of globular cells in each mosaic, in cells/mm2 of mosaic area. |
List of clinical and demographic parameters linked to each study subject in the provided data set.
| Parameter | Description |
|---|---|
| Subject ID | Identification number of the subject in the cohort (57 subjects of which 2 were excluded). |
| Study Group | Controls, PD + RLS, or PD − RLS |
| Age | Subject age at time of study inclusion (years) |
| Sex | 1 = Male, 0 = Female |
| Smoking | Smoking status, 1 = yes, 0 = no |
| Coffee intake | Consumption of coffee (cups/day) |
| Intake of B12 supplements or multivitamins | 1 = yes, 0 = no |
| PD motor duration | Duration of motor symptoms (years) |
| RLS duration | Duration of restless legs syndrome (years) |
| L-dopa duration | Duration of treatment with L-dopa (years) |
| LEDD | L-dopa equivalent daily dose (mg) |
| Ongoing L-dopa therapy | 1 = yes, 0 = no |
| mH&Y (stage) | Modified Hoehn and Yahr scale for staging Parkinson’s symptoms and disability |
| IRLS | International RLS study group rating scale (IRLS): 0–40 |
| UENS | Utah Early Neuropathy Scale. Clinical rating scale for the assessment of peripheral neuropathy. |
| p-homocysteine | Concentration of homocysteine in plasma (μmol/L) |
| s-methylmalonic acid | Concentration of methylmalonic acid in serum (μmol/L) |
| p-pyridoxal-5′-phosphate | Concentration of pyridoxal-5′-phosphate in plasma (nmol/L) |
| s-ferritin | Concentration of ferritin in serum (μg/L) |
Blood parameters were based on fasting whole blood samples acquired using venipuncture. L-dopa: Levodopa.
Fig. 1Characterization of mosaic computation and size. (a) Scatter plot for run-times for mosaic image generation in relation to mosaic image size. (b) Histogram of distribution of number of mosaics for each enhancement factor (enhancement factor is mosaic area divided by the area of a single 400 × 400 μm IVCM frame).
Fig. 2Representative IVCM mosaic images of the corneal subbasal nerve plexus for the three study groups. (a) Control. (b) Subject with PD with RLS. (c) Subject with PD without RLS.
Fig. 3Mosaic image illustrating regions analyzed for inferocentral whorl parameter wCNFL. (a) Mosaic image depicting region of 800 μm radius (blue) and 400 μm radius (magenta) centered on the whorl center. (b) Mosaic image depicting upper half circle of 800 μm radius (blue) and 400 μm radius (magenta) based on the whorl center.
Fig. 4Box plots comparing mCNFL among the study groups. (a) Box plot comparing healthy controls vs. all Parkinson’s disease (PD) patients as a single group, t-test P = 0.62. (b) Box plot comparing all study subgroups including PD patients with and without RLS, ANOVA P = 0.79. Data represents quantification based on the single largest mosaic per eye, differing slightly from prior analyses where in some cases average values from several mosaics per eye were used[30].
Fig. 5Box plots indicating comparisons of wCNFL across study groups. (a,b) Comparison of wCNFL across the three study groups. (a) Full circular whorl region of 800 μm diameter, ANOVA P = 0.47. (b) Half-circle region of 800 μm diameter, ANOVA P = 0.77. (c,d) The corresponding box plots for the whorl defined in a 400 μm diameter region. (c) Full circular whorl region of 400 μm diameter, ANOVA P = 0.36. (d) Half-circle region of 400 μm diameter, ANOVA P = 0.47.
Overview of inter-observer differences in dendritic cell quantification from mosaic images.
| Inflammatory cell type | |||
|---|---|---|---|
| mDCs | imDCs | GCs | |
| Mean difference | 9.3 | −4.9 | −0.8 |
| SD | 12.7 | 30.0 | 2.6 |
| Lower 95% LOA | −15.6 | −63.8 | −5.9 |
| Upper 95% LOA | 34.3 | 54.0 | 4.3 |
| Pearson’s r | 0.68 | 0.74 | 0.98 |
Values represent the mean difference between the two observers, standard deviation of difference and lower and upper bounds of the 95% limits of agreement (LOA) for dendritic cell density in cells/mm2 of mosaic area, for each given cell type. Identification and quantification of inflammatory cells was based on three cell types: mDCs: Mature dendritic cells, imDCs: immature dendritic cells, and GCs: globular cells. The correlation coefficient between observers (Pearson’s r) is shown for each cell type.
Fig. 6Box plots indicating comparisons for inflammatory cells across study groups. (a) Density of mature dendritic cells (mDCs), ANOVA P = 0.58. (b) Density of immature dendritic cells (imDCs), ANOVA P = 0.54. (c) Density of globular cells (GCs), ANOVA P = 0.19.
| Measurement(s) | Prominent corneal nerve fibers • Dendritic Cell |
| Technology Type(s) | confocal microscopy |
| Factor Type(s) | disease status • comorbidity |
| Sample Characteristic - Organism | Homo sapiens |